Cabozantinib for treating medullary thyroid cancer (TA516)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2018
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Etelcalcetide for treating secondary hyperparathyroidism (TA448)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2017
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2018
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 March 2020
Teprotumumab for treating thyroid eye disease ID6432Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vandetanib for treating medullary thyroid cancer (TA550)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2018